• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Evaluation of the COVID-19 vaccine effectiveness on the outcomes of COVID 19 disease in Iran: a test-negative case-control study

tetano

Editor, Senior Moderator
Front Immunol


. 2024 Aug 20:15:1420651.
doi: 10.3389/fimmu.2024.1420651. eCollection 2024. Evaluation of the COVID-19 vaccine effectiveness on the outcomes of COVID 19 disease in Iran: a test-negative case-control study

Fatemeh Khosravi Shadmani[SUP] 1 [/SUP], Ghobad Moradi[SUP] 2 [/SUP], Mohammadreza Naghipour[SUP] 3 [/SUP], Fatemeh Torkaman Asadi[SUP] 4 [/SUP], Ali Ahmadi[SUP] 5 [/SUP], Alireza Mirahmadizadeh[SUP] 6 [/SUP], Ali Akbar Haghdoost[SUP] 7 [/SUP], Bita Mesgarpour[SUP] 8 [/SUP], Seyed Mohsen Zahraei[SUP] 9 [/SUP], Mohammad Mehdi Goya[SUP] 9 [/SUP], Majid Mokhtari[SUP] 10 [/SUP], Roya Safari-Faramani[SUP] 11 [/SUP], Fariba Zomorrodi Zare[SUP] 1 [/SUP], Maryam Chegeni[SUP] 12 [/SUP], Farid Najafi[SUP] 1 [/SUP]



Affiliations
Abstract

Introduction: This study measures the COVID-19 vaccine effectiveness (CVE) against hospital admission and severe COVID-19.
Methods: This study is a test-negative case-control design using data from eight provinces in April, 2021 until March, 2022. The individuals were classified as cases and controls based on the results of the RT-PCR test for SARS-CoV-2 and matched based on the timing of the test being conducted as well as the timing of hospital admission. The measure of association was an odds ratio (OR) by univariate and multiple logistic regression. The multiple logistic regression has been carried out to take confounding factors and potential effect modifiers into account. The CVE was computed as CVE = (1 - OR)*100 with 95% confidence interval.
Results: Among 19314 admitted patients, of whom 13216 (68.4%) were cases and 6098 (31.6%) were controls, 1313 (6.8%) died. From total, 5959 (30.8%) patients had received the vaccine in which one, two, and booster doses were 2443 (12.6%), 2796 (14.5٪), and 720 (3.7٪), respectively. The estimated adjusted effectiveness of only one dose, two doses and booter vaccination were 22% (95% CI: 14%-29%), 35% (95% CI: 29%-41%) and 33% (95% CI: 16%-47%), respectively. In addition, the adjusted vaccine effectiveness against severe outcome was 33% (95% CI: 19%- 44%), 34% (95% CI: 20%- 45%) and 20% (95% CI: -29%- 50%) for those who received one, two and booster vaccinations, respectively.
Conclusion: Our study concluded that full vaccination, though less effective compared to similar studies elsewhere, decreased hospital admissions and deaths from COVID-19 in Iran, particularly during the Delta variant period, with an observed decline during the Omicron variant dominance.

Keywords: COVID-19; Iran; death; hospital admission; test-negative case-control; vaccine effectiveness.

 
Back
Top Bottom